A  ||| S:0 E:2 ||| DT
comparative  ||| S:2 E:14 ||| JJ
evaluation  ||| S:14 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
the  ||| S:28 E:32 ||| DT
systemic  ||| S:32 E:41 ||| JJ
and  ||| S:41 E:45 ||| CC
local  ||| S:45 E:51 ||| JJ
alendronate  ||| S:51 E:63 ||| JJ
treatment  ||| S:63 E:73 ||| NN
in  ||| S:73 E:76 ||| IN
synthetic  ||| S:76 E:86 ||| JJ
bone  ||| S:86 E:91 ||| NN
graft ||| S:91 E:96 ||| NNS
:  ||| S:96 E:98 ||| :
a  ||| S:98 E:100 ||| DT
histologic  ||| S:100 E:111 ||| NN
and  ||| S:111 E:115 ||| CC
histomorphometric  ||| S:115 E:133 ||| JJ
study  ||| S:133 E:139 ||| NN
in  ||| S:139 E:142 ||| IN
a  ||| S:142 E:144 ||| DT
rat  ||| S:144 E:148 ||| JJ
calvarial  ||| S:148 E:158 ||| JJ
defect  ||| S:158 E:165 ||| NN
model  ||| S:165 E:171 ||| NN
The  ||| S:171 E:175 ||| DT
purpose  ||| S:175 E:183 ||| NN
of  ||| S:183 E:186 ||| IN
this  ||| S:186 E:191 ||| DT
study  ||| S:191 E:197 ||| NN
was  ||| S:197 E:201 ||| VBD
to  ||| S:201 E:204 ||| TO
compare  ||| S:204 E:212 ||| VB
the  ||| S:212 E:216 ||| DT
relative  ||| S:216 E:225 ||| JJ
efficacy  ||| S:225 E:234 ||| NN
of  ||| S:234 E:237 ||| IN
systemic  ||| S:237 E:246 ||| JJ
and  ||| S:246 E:250 ||| CC
local  ||| S:250 E:256 ||| JJ
alendronate  ||| S:256 E:268 ||| JJ
treatment  ||| S:268 E:278 ||| NN
of  ||| S:278 E:281 ||| IN
synthetic  ||| S:281 E:291 ||| JJ
bone  ||| S:291 E:296 ||| NN
graft  ||| S:296 E:302 ||| NN
in  ||| S:302 E:305 ||| IN
a  ||| S:305 E:307 ||| DT
rat  ||| S:307 E:311 ||| JJ
calvarial  ||| S:311 E:321 ||| JJ
defect  ||| S:321 E:328 ||| NN
model ||| S:328 E:333 ||| NN
.  ||| S:333 E:335 ||| .
Forty  ||| S:335 E:341 ||| NNP
Wistar  ||| S:341 E:348 ||| NNP
rats  ||| S:348 E:353 ||| NNS
were  ||| S:353 E:358 ||| VBD
divided  ||| S:358 E:366 ||| VBN
into  ||| S:366 E:371 ||| IN
4  ||| S:371 E:373 ||| CD
groups ||| S:373 E:379 ||| NNS
:  ||| S:379 E:381 ||| :
experimental  ||| S:381 E:394 ||| JJ
animals  ||| S:394 E:402 ||| NNS
received  ||| S:402 E:411 ||| VBD
alendronate  ||| S:411 E:423 ||| JJ
systemically  ||| S:423 E:436 ||| NN
or  ||| S:436 E:439 ||| CC
locally  ||| S:439 E:447 ||| RB
combined  ||| S:447 E:456 ||| VBN
with  ||| S:456 E:461 ||| IN
micro-macroporous  ||| S:461 E:479 ||| FW
biphasic  ||| S:479 E:488 ||| FW
calcium  ||| S:488 E:496 ||| FW
phosphate  ||| S:496 E:506 ||| FW
( ||| S:506 E:507 ||| -LRB-
MBCP ||| S:507 E:511 ||| NNP
)  ||| S:511 E:513 ||| -RRB-
graft  ||| S:513 E:519 ||| JJ
material ||| S:519 E:527 ||| NN
.  ||| S:527 E:529 ||| .
In  ||| S:529 E:532 ||| IN
the  ||| S:532 E:536 ||| DT
control  ||| S:536 E:544 ||| NN
group ||| S:544 E:549 ||| NN
,  ||| S:549 E:551 ||| ,
the  ||| S:551 E:555 ||| DT
defect  ||| S:555 E:562 ||| NN
was  ||| S:562 E:566 ||| VBD
left  ||| S:566 E:571 ||| VBN
empty ||| S:571 E:576 ||| JJ
.  ||| S:576 E:578 ||| .
On  ||| S:578 E:581 ||| IN
each  ||| S:581 E:586 ||| DT
animal ||| S:586 E:592 ||| NN
,  ||| S:592 E:594 ||| ,
a  ||| S:594 E:596 ||| DT
5-mm  ||| S:596 E:601 ||| JJ
standardized  ||| S:601 E:614 ||| JJ
bone  ||| S:614 E:619 ||| NN
defect  ||| S:619 E:626 ||| NN
was  ||| S:626 E:630 ||| VBD
created  ||| S:630 E:638 ||| VBN
with  ||| S:638 E:643 ||| IN
a  ||| S:643 E:645 ||| DT
standard  ||| S:645 E:654 ||| JJ
trephine  ||| S:654 E:663 ||| JJ
bur  ||| S:663 E:667 ||| NN
in  ||| S:667 E:670 ||| IN
calvarium ||| S:670 E:679 ||| NN
.  ||| S:679 E:681 ||| .
All  ||| S:681 E:685 ||| DT
animals  ||| S:685 E:693 ||| NNS
were  ||| S:693 E:698 ||| VBD
killed  ||| S:698 E:705 ||| VBN
after  ||| S:705 E:711 ||| IN
8  ||| S:711 E:713 ||| CD
weeks ||| S:713 E:718 ||| NNS
.  ||| S:718 E:720 ||| .
The  ||| S:720 E:724 ||| DT
number  ||| S:724 E:731 ||| NN
of  ||| S:731 E:734 ||| IN
osteoclasts ||| S:734 E:745 ||| NN
,  ||| S:745 E:747 ||| ,
osteoclast  ||| S:747 E:758 ||| JJ
morphology ||| S:758 E:768 ||| NN
,  ||| S:768 E:770 ||| ,
resorption  ||| S:770 E:781 ||| JJ
lacunae ||| S:781 E:788 ||| NN
,  ||| S:788 E:790 ||| ,
osteoblastic  ||| S:790 E:803 ||| JJ
activity ||| S:803 E:811 ||| NN
,  ||| S:811 E:813 ||| ,
and  ||| S:813 E:817 ||| CC
lamellar  ||| S:817 E:826 ||| JJ
bone  ||| S:826 E:831 ||| NN
formation  ||| S:831 E:841 ||| NN
were  ||| S:841 E:846 ||| VBD
histopathologically  ||| S:846 E:866 ||| JJ
evaluated  ||| S:866 E:876 ||| NN
and  ||| S:876 E:880 ||| CC
the  ||| S:880 E:884 ||| DT
newly  ||| S:884 E:890 ||| RB
formed  ||| S:890 E:897 ||| VBN
bone  ||| S:897 E:902 ||| NN
area  ||| S:902 E:907 ||| NN
was  ||| S:907 E:911 ||| VBD
analyzed  ||| S:911 E:920 ||| JJ
histomorphometrically ||| S:920 E:941 ||| NN
.  ||| S:941 E:943 ||| .
Eight  ||| S:943 E:949 ||| CD
weeks  ||| S:949 E:955 ||| NNS
after  ||| S:955 E:961 ||| IN
surgery ||| S:961 E:968 ||| NN
,  ||| S:968 E:970 ||| ,
the  ||| S:970 E:974 ||| DT
number  ||| S:974 E:981 ||| NN
of  ||| S:981 E:984 ||| IN
osteoclasts  ||| S:984 E:996 ||| NN
and  ||| S:996 E:1000 ||| CC
the  ||| S:1000 E:1004 ||| DT
resorption  ||| S:1004 E:1015 ||| JJ
lacunae  ||| S:1015 E:1023 ||| NN
in  ||| S:1023 E:1026 ||| IN
the  ||| S:1026 E:1030 ||| DT
MBCP  ||| S:1030 E:1035 ||| NNP
group  ||| S:1035 E:1041 ||| NN
using  ||| S:1041 E:1047 ||| VBG
systemic  ||| S:1047 E:1056 ||| JJ
alendronate  ||| S:1056 E:1068 ||| JJ
therapy  ||| S:1068 E:1076 ||| NN
was  ||| S:1076 E:1080 ||| VBD
significantly  ||| S:1080 E:1094 ||| RB
higher  ||| S:1094 E:1101 ||| JJR
than  ||| S:1101 E:1106 ||| IN
those  ||| S:1106 E:1112 ||| DT
of  ||| S:1112 E:1115 ||| IN
the  ||| S:1115 E:1119 ||| DT
other  ||| S:1119 E:1125 ||| JJ
groups  ||| S:1125 E:1132 ||| NNS
( ||| S:1132 E:1133 ||| -LRB-
P  ||| S:1133 E:1135 ||| NNP
< ||| S:1135 E:1137 ||| SYM
.05 ||| S:1137 E:1140 ||| NNP
) ||| S:1140 E:1141 ||| -RRB-
.  ||| S:1141 E:1143 ||| .
Osteoblast  ||| S:1143 E:1154 ||| JJ
number  ||| S:1154 E:1161 ||| NN
in  ||| S:1161 E:1164 ||| IN
the  ||| S:1164 E:1168 ||| DT
MBCP  ||| S:1168 E:1173 ||| NNP
group  ||| S:1173 E:1179 ||| NN
using  ||| S:1179 E:1185 ||| VBG
systemic  ||| S:1185 E:1194 ||| JJ
alendronate  ||| S:1194 E:1206 ||| JJ
treatment  ||| S:1206 E:1216 ||| NN
was  ||| S:1216 E:1220 ||| VBD
significantly  ||| S:1220 E:1234 ||| RB
increased  ||| S:1234 E:1244 ||| VBN
( ||| S:1244 E:1245 ||| -LRB-
P  ||| S:1245 E:1247 ||| NNP
< ||| S:1247 E:1249 ||| SYM
.05 ||| S:1249 E:1252 ||| NNP
) ||| S:1252 E:1253 ||| -RRB-
.  ||| S:1253 E:1255 ||| .
No  ||| S:1255 E:1258 ||| DT
significant  ||| S:1258 E:1270 ||| JJ
difference  ||| S:1270 E:1281 ||| NN
was  ||| S:1281 E:1285 ||| VBD
found  ||| S:1285 E:1291 ||| VBN
among  ||| S:1291 E:1297 ||| IN
all  ||| S:1297 E:1301 ||| DT
MBCP  ||| S:1301 E:1306 ||| NNP
groups  ||| S:1306 E:1313 ||| NNS
using  ||| S:1313 E:1319 ||| VBG
local  ||| S:1319 E:1325 ||| JJ
or  ||| S:1325 E:1328 ||| CC
systemic  ||| S:1328 E:1337 ||| JJ
alendronate  ||| S:1337 E:1349 ||| JJ
treatments  ||| S:1349 E:1360 ||| NNS
with  ||| S:1360 E:1365 ||| IN
regard  ||| S:1365 E:1372 ||| NN
to  ||| S:1372 E:1375 ||| TO
new  ||| S:1375 E:1379 ||| JJ
bone  ||| S:1379 E:1384 ||| NN
formation  ||| S:1384 E:1394 ||| NN
( ||| S:1394 E:1395 ||| -LRB-
P  ||| S:1395 E:1397 ||| NNP
>  ||| S:1397 E:1399 ||| NNP
.05 ||| S:1399 E:1402 ||| NNP
) ||| S:1402 E:1403 ||| -RRB-
.  ||| S:1403 E:1405 ||| .
Within  ||| S:1405 E:1412 ||| IN
the  ||| S:1412 E:1416 ||| DT
limits  ||| S:1416 E:1423 ||| NNS
of  ||| S:1423 E:1426 ||| IN
the  ||| S:1426 E:1430 ||| DT
study ||| S:1430 E:1435 ||| NN
,  ||| S:1435 E:1437 ||| ,
alendronate ||| S:1437 E:1448 ||| NN
,  ||| S:1448 E:1450 ||| ,
when  ||| S:1450 E:1455 ||| WRB
administered  ||| S:1455 E:1468 ||| JJ
systemically  ||| S:1468 E:1481 ||| NN
or  ||| S:1481 E:1484 ||| CC
locally ||| S:1484 E:1491 ||| RB
,  ||| S:1491 E:1493 ||| ,
did  ||| S:1493 E:1497 ||| VBD
not  ||| S:1497 E:1501 ||| RB
increase  ||| S:1501 E:1510 ||| VB
bone  ||| S:1510 E:1515 ||| JJ
regeneration  ||| S:1515 E:1528 ||| NN
with  ||| S:1528 E:1533 ||| IN
MBCP  ||| S:1533 E:1538 ||| NNP
graft  ||| S:1538 E:1544 ||| NN
in  ||| S:1544 E:1547 ||| IN
the  ||| S:1547 E:1551 ||| DT
rat  ||| S:1551 E:1555 ||| JJ
calvarial  ||| S:1555 E:1565 ||| JJ
defect  ||| S:1565 E:1572 ||| NN
model ||| S:1572 E:1577 ||| NN
.  ||| S:1577 E:1579 ||| .
